Contemporary Concise Review 2022: Interstitial lung disease.
David J F SmithR Gisli JenkinsPublished in: Respirology (Carlton, Vic.) (2023)
Novel genetic associations for idiopathic pulmonary fibrosis (IPF) risk have been identified. Common genetic variants associated with IPF are also associated with chronic hypersensitivity pneumonitis. The characterization of underlying mechanisms, such as pathways involved in myofibroblast differentiation, may reveal targets for future treatments. Newly identified circulating biomarkers are associated with disease progression and mortality. Deep learning and machine learning may increase accuracy in the interpretation of CT scans. Novel treatments have shown benefit in phase 2 clinical trials. Hospitalization with COVID-19 is associated with residual lung abnormalities in a substantial number of patients. Inequalities exist in delivering and accessing interstitial lung disease specialist care.
Keyphrases
- interstitial lung disease
- idiopathic pulmonary fibrosis
- machine learning
- deep learning
- systemic sclerosis
- clinical trial
- end stage renal disease
- palliative care
- computed tomography
- chronic kidney disease
- coronavirus disease
- healthcare
- genome wide
- rheumatoid arthritis
- ejection fraction
- artificial intelligence
- newly diagnosed
- dual energy
- sars cov
- prognostic factors
- cardiovascular disease
- type diabetes
- cardiovascular events
- magnetic resonance imaging
- transforming growth factor
- risk factors
- signaling pathway
- positron emission tomography
- current status